Skip to main content

CASE REPORT article

Front. Neurol., 13 June 2022
Sec. Multiple Sclerosis and Neuroimmunology
This article is part of the Research Topic Multiple Sclerosis and Neuroimmunology – Case Report Collection, Volume II View all 35 articles

Anti-homer-3 Antibody Encephalitis in a 10-Year-Old Child: Case Report and Review of the Literature

\nZuying Kuang&#x;Zuying Kuang1Jos Fidel Baizabal-Carvallo,&#x;José Fidel Baizabal-Carvallo2,3Mohammad MofattehMohammad Mofatteh4Sifen XieSifen Xie1Zhanhang Wang
Zhanhang Wang1*Yimin Chen
Yimin Chen5*
  • 1Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou, China
  • 2Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, United States
  • 3Department of Sciences and Engineering, University of Guanajuato, León, Mexico
  • 4School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom
  • 5Department of Neurology, Foshan Sanshui District People's Hospital, Foshan, China

Objective: We present a rare case with anti-Homer-3 antibodies positive encephalitis in the youngest patient ever identified and reviewed the literature.

Case Report: A 10-year-old, Chinese boy came for evaluation of a 2-week history of cognitive impairment, irritability, dysarthria, and cautious gait. The neurological examination was consistent with the pan-cerebellar syndrome and encephalopathy. Cerebrospinal fluid (CSF) was inflammatory with increased leukocytes. Magnetic resonance imaging of the brain showed hyperintensities in both cerebellar hemispheres and vermis in Fluid-attenuated inversion recovery (FLAIR) and T2- weighted sequences. Infectious disorders were ruled out, but positivity for anti-Homer-3 antibodies was detected in the CSF, but not in the serum. Additionally, low titers of voltage-gated calcium channel (VGCC) antibodies were found in the serum. Treatment with intravenous (IV) corticosteroids did not provide meaningful clinical improvement; however, the patient achieved almost complete recovery (modified Ranking Scale score: 1) following IV immunoglobulin.

Conclusion: Anti-Homer-3 cerebellar ataxia with encephalopathy should be considered within the differential diagnosis of acute inflammatory cerebellar disease in children and it may coexist with VGCC antibodies.

Introduction

Cerebellar ataxia may be associated with genetic and acquired causes. Among the latter, an autoimmune or paraneoplastic etiology should be considered within the differential diagnosis. Anti-Homer-3 antibody encephalitis is a rare cause of autoimmune cerebellar ataxia first described in 2007 by Zuliani and colleagues, in a patient with subacute cerebellar ataxia (1). Anti-Homer-3 cerebellar ataxia is mostly described in adult patients, with the youngest patient being 14 years old (2). In this manuscript, we report a case of anti-Homer-3 cerebellar ataxia in a 10-year-old child, analyze the clinical profile of anti-Homer-3 autoimmunity, and contrast it with a closely related molecular disorder involving metabotropic glutamate receptor 1 (mGlutR1) autoimmunity.

Case Report

A 10-year-old, right-handed, Chinese patient presented for clinical evaluation of a 2-week history characterized by impaired concentration, irritable mood, slurred speech, and slow, cautious gait. There was no recent history of an infectious disorder. The neurologic examination revealed bradypsychia, dysarthria, and downbeat nystagmus. The patient had dysmetria and dysdiadochokinesia. Tandem gait showed frank ataxia. Romberg's sign was negative.

Initial investigation showed normal blood cell count, lactic acid levels, d-dimer assays, and hepatic and renal function tests. Serology for hepatitis C and HIV type 1 and 2 were negative. A lumbar puncture revealed an opening pressure of 16.5 cm/H2O. Cerebrospinal fluid (CSF) protein was 0.3 g/L (0.15–0.45 g/L), lactic dehydrogenase was 40.5 U/L ( ≤ 70 U/L), granular leukocytes were 30 × 106/L (0–5 × 106/L), and glucose and chloride levels were normal. Ziehl-Neelsen staining for acid-fast bacilli and Cryptococcus neoformans smear test in the CSF were negative. We used tissue-based assay by indirect immunofluorescence in fixed rat brain slices to screen for antibodies reacting with central nervous system antigens. Then, we used a commercially available cell-based assay to check for interest antibodies. Anti-Homer-3 antibody was positive in the CSF (1:1) (Figure 1) cell-based assay; however, the test was negative in the serum. Other antibodies such as anti-NMDAR, anti-AMPA1, anti-AMPA2, anti-CASPR2, anti-DPPX, anti-DRD2, anti-GlyR, anti-GAD65, anti-GABAB, anti-IgLON5, anti-LGI1, anti-mGlutR1, and anti-mGlutR5, as well as onconeural antibodies, were negative; however, low titers of anti-voltage gated calcium channel antibodies (VGCC-antibodies) were found in the serum: 41 pmol/L (normal value ≤ 30 pmol/L).

FIGURE 1
www.frontiersin.org

Figure 1. The anti-Homer-3 antibody of CSF was positive. (A) The green marker represents Homer-3 antigen, (B) the red marker represents anti-Homer-3 antibody; (C) the third one is fluorescence overlap. The images were taken using Olympus IX73 microscopy. The scale bar is 50 μm.

A detailed ultrasound examination of abdominal and pelvic structures was normal without evidence of tumor and a chest X-ray was unremarkable.

Brain magnetic resonance imaging (MRI) showed hyperintensities in both cerebellar hemispheres and vermis in FLAIR and T2-weighted (T2W) sequences (Figures 2A,B).

FIGURE 2
www.frontiersin.org

Figure 2. (A,B) initial MRI: right cerebellar atrophy and multiple lesions in bilateral cerebellum and vermis. (C,D) follow-up MRI showed bilateral cerebellum and vermis atrophy, sulcus of left cerebellum was wider.

Initial treatment was carried out with intravenous boluses of methylprednisolone (1 g per day for 5 days), followed by oral prednisolone at decreasing doses for 15 days. No improvement was observed on day 10; for that reason, intravenous immunoglobulin (IVIg) was offered, but the patient's parents initially declined for personal reasons.

As no improvement in cognitive and motor condition was observed in the following weeks, the patient's parents accepted treatment with IVIg 1 month after the initial assessment. Slow but progressive clinical improvement was noticed with normalization of cognitive impairment and cerebellar syndrome a year later March 1, 2022, when only mild dysarthria was noticed, a score of 1 on the modified Rankin Scale was registered at that time. Follow-up MRI showed mild cerebellar atrophy (Figures 2C,D).

Discussion

We report the youngest case ever with autoimmune encephalitis associated with anti-Homer-3 antibodies in a 10-year-old child, manifested by encephalopathy, cerebellar ataxia, and hyperintensities in the cerebellum. Acute and subacute cerebellar ataxia may follow diverse etiologies in children, including nutritional, toxic, post-infectious (e.g., Epstein-Barr, herpes simplex, measles, mumps, parvovirus B19, varicella, Mycoplasma, etc.), or autoimmune. Most of these causes do not show signs of inflammation in the cerebellum when assessed by MRI (3). However, few cases of post-infectious cerebellitis may present with cerebellar hyperintensities on MRI followed by cerebellar atrophy (4). Patients with post-infectious cerebellar ataxia usually show a prodromal period with a febrile illness, followed by frank cerebellar ataxia; this was not observed in our patient. Moreover, acute cerebellitis in children may be observed with metronidazole and vigabatrin therapy, these patients show a distinctive pattern on MRI with pons and dentate nuclei hyperintensities (5). While a paraneoplastic or an ischemic etiology is more commonly seen in adults with acute cerebellar ataxia, these etiologies are less common in children, which varies the clinical approach. Autoimmune cerebellar ataxia in children may be related to anti-glutamic acid decarboxylase (anti-GAD) antibodies, gluten ataxia, or the cerebellar variant of Hashimoto's encephalitis, but other etiologies have been rarely described (3).

Most patients reported with anti-Homer-3 autoimmunity are adults with cerebellar ataxia as the most common presentation; however, other neurologic manifestations, such as encephalopathy, seizures, myeloradiculopathy, radiculoneuropathy, autonomic neuropathy, and REM-sleep behavior disorder (RBD), have been described (Table 1) (68). Although the number of reported cases in the literature is small, multiple system atrophy cerebellar subtype C (MSA-C)-like syndrome with brainstem and cerebellar atrophy along with RBD has been reported in adults; whereas inflammation with diffuse hyperintensities in the cerebellum has been only observed in young individuals: 14 and 10-year-old patients as described in this report (Table 1).

TABLE 1
www.frontiersin.org

Table 1. Summary of reported clinical cases of anti-Homer-3 associated autoimmunity.

The Homer-3 antigen is enriched in the dendritic spines of cerebellar Purkinje cells and is also expressed in their cell bodies and axons (9). The cerebellar cortex, hippocampus, and non-neuronal tissues (e.g., thymus and lung) also express the Homer-3 antigen (9). Homer-3 interacts with the metabotropic glutamate receptor 1 (mGluR1) C-terminus in Purkinje cells to regulate its trafficking and clustering in the cell membrane to modulate its functional activity (9). Autoimmunity related to anti-mGluR1 antibodies has been described in a larger number of patients; there are several similar features between anti-Homer-3 and anti-mGlutR1 autoimmunity (Table 2), suggesting biological convergence between both disorders. However, it should be noticed, that while there is compelling in vitro and in vivo evidence that anti-mGlutR1 autoimmunity is related to pathogenic antibodies (1, 10), anti-Homer-3 autoimmunity is more likely to be related to cellular toxicity as the antigen is intracellular.

TABLE 2
www.frontiersin.org

Table 2. Differences between Homer-3 and mGluR1 autoimmunity.

Patients with anti-Homer-3 autoimmunity seem to have a worse prognosis and lower response rate to immunotherapy than patients with anti-mGlutR1 antibodies (Table 2), although direct comparisons are lacking (10, 11). A previous study reported that among six patients with anti-Homer-3 autoimmunity who received immunotherapy, four improved, but still showed residual disability with a modified Ranking Scale ≤ 2 at the last follow-up; moreover, relapses, might present following initial remission or improvement with immunosuppressant (8). However, whether all patients with anti-Homer-3 autoimmunity should undergo prolonged immunosuppression with medications, such as azathioprine or mycophenolate mofetil, is unclear.

Voltage-gated calcium channel antibodies are associated with Lambert-Eaton myasthenic syndrome, characterized by proximal muscle weakness, areflexia, and autonomic dysfunction; none of these features were observed in our patient (12). Anti-VGCC antibodies are paraneoplastic in about 90% of cases in the context of cerebellar ataxia, mainly associated with small cell lung cancer (SCLC); there was no evidence of underlying neoplasm in our patient. Some patients with positive anti-VGCC antibodies may present with non-paraneoplastic cerebellar degeneration, responding to immunotherapy (13). We cannot rule out that these antibodies contributed to the clinical manifestations in our patient; however, much higher serum titers between 500 and 648 pM/L have been reported in patients with paraneoplastic and non-paraneoplastic cerebellar ataxia (13, 14); moreover, we are not aware of VGCC autoimmunity presenting with signs of cerebellar inflammation in the MRI.

Conclusions

Autoimmunity related to anti-Homer-3 is mostly identified in adults, but may also present in children. Although data is scarce, it seems that in this age group, patients present with signs of cerebellar inflammation on MRI preceding cerebellar atrophy, contrasting with cerebellar, and brainstem atrophy observed at presentation and during the disease in adult patients. Anti-Homer-3 autoimmunity should be considered within the differential diagnosis of autoimmune cerebellar ataxia in childhood. Negative serum antibodies do not rule out the disorder as anti-Homer-3 antibodies may be present only in the CSF.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics Statement

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

Author Contributions

YC, ZK, ZW, and SX conceived the study, gathered the data, and drafted the manuscript. JB-C and MM conceived the study, review, and critique. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflictof interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

The authors would like to thank the patient and family.

References

1. Zuliani L, Sabater L, Saiz A, Baiges JJ, Giometto B, Graus F. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology. (2007) 68:239–40. doi: 10.1212/01.wnl.0000251308.79366.f9

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Garza M, Piquet AL. Update in autoimmune movement disorders: newly described antigen targets in autoimmune and paraneoplastic cerebellar ataxia. Front Neurol. (2021) 12:683048. doi: 10.3389/fneur.2021.683048

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Fogel BL. Childhood cerebellar ataxia. J Child Neurol. (2012) 27:1138–45. doi: 10.1177/0883073812448231

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Bakshi R, Bates VE, Kinkel PR, Mechtler LL, Kinkel WR. Magnetic resonance imaging findings in acute cerebellitis. Clin Imaging. (1998) 22:79–85. doi: 10.1016/S0899-7071(97)00093-4

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Singh R, Kaur R, Pokhariyal P, Aggarwal R. Sequential MR imaging (with diffusion-weighted imaging) changes in metronidazole-induced encephalopathy. Indian J Radiol Imaging. (2017) 27:129–32. doi: 10.4103/ijri.IJRI_341_16

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Höftberger R, Sabater L, Ortega A, Dalmau J, Graus F. Patient with homer-3 antibodies and cerebellitis. JAMA Neurol. (2013) 70:506–9. doi: 10.1001/jamaneurol.2013.1955

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Xu X, Ren H, Li L, Wang J, Fechner K, Guan H. Anti-Homer-3 antibody associated cerebellar ataxia: a rare case report and literature review. J Neuroimmunol. (2019) 330:155–8. doi: 10.1016/j.jneuroim.2019.01.002

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Liu M, Ren H, Fan S, Zhang W, Xu Y, Zhao W, et al. Neurological autoimmunity associated with homer-3 antibody: a case series from China. Neurol Neuroimmunol Neuroinflamm. (2021) 8:e1077. doi: 10.1212/NXI.0000000000001077

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Xiao B, Tu JC, Petralia RS, Yuan JP, Doan A, Breder CD, et al. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron. (1998) 21:707–16. doi: 10.1016/S0896-6273(00)80588-7

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Spatola M, Petit Pedrol M, Maudes E, Simabukuro M, Muñiz-Castrillo S, Pinto AL, et al. Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology. (2020) 95:e3012–25. doi: 10.1212/WNL.0000000000010854

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Lopez-Chiriboga AS, Komorowski L, Kümpfel T, Probst C, Hinson SR, Pittock SJ, et al. Metabotropic glutamate receptor type 1 autoimmunity: clinical features and treatment outcomes. Neurology. (2016) 86:1009–13. doi: 10.1212/WNL.0000000000002476

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Bekircan-Kurt CE, Derle Çiftçi E, Kurne AT, Anlar B. Voltage gated calcium channel antibody-related neurological diseases. World J Clin Cases. (2015) 3:293–300. doi: 10.12998/wjcc.v3.i3.293

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Rigamonti A, Lauria G, Stanzani L, Mantero V, Andreetta F, Salmaggi A. Non-paraneoplastic voltage-gated calcium channels antibody-mediated cerebellar ataxia responsive to IVIG treatment. J Neurol Sci. (2014) 336:169–70. doi: 10.1016/j.jns.2013.10.031

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. (2002) 59:764–6. doi: 10.1212/WNL.59.5.764

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: anti-homer-3 antibody, autoimmune encephalitis, antibodies, cerebellar ataxia, children

Citation: Kuang Z, Baizabal-Carvallo JF, Mofatteh M, Xie S, Wang Z and Chen Y (2022) Anti-homer-3 Antibody Encephalitis in a 10-Year-Old Child: Case Report and Review of the Literature. Front. Neurol. 13:929778. doi: 10.3389/fneur.2022.929778

Received: 27 April 2022; Accepted: 16 May 2022;
Published: 13 June 2022.

Edited by:

Robert Weissert, University of Regensburg, Germany

Reviewed by:

Sergio Muñiz-Castrillo, Stanford Center for Sleep Sciences and Medicine, United States
Suvasini Sharma, University of Delhi, India
Hongjun Hao, Peking University First Hospital, China

Copyright © 2022 Kuang, Baizabal-Carvallo, Mofatteh, Xie, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yimin Chen, drymchen@126.com; Zhanhang Wang, kedafu2005@sina.com

These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.